SA
SMMT icon

Seneschal Advisors’s Summit Therapeutics SMMT Stock Holding History

Seneschal Advisors’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19 Sell
1
-1
-50% -$16 ﹤0.01% 593
2025
Q4 		$35 Hold
2
– – ﹤0.01% 588
2025
Q3 		$42 Buy
+2
New +$49 ﹤0.01% 585

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Seneschal Advisors's SMMT Position: Q1 2026 in Review

Seneschal Advisors reduced its Summit Therapeutics (SMMT) stake by 50% in Q1 2026, selling an estimated $16 and leaving 1 share worth $19. The position accounts for ﹤0.01% of the portfolio, ranked #593.

Seneschal Advisors first reported a position in SMMT in Q3 2025 and has held it in 3 quarters since. The position peaked at $42 in Q3 2025. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • Seneschal Advisors held 1 share of Summit Therapeutics worth $19 as of Q1 2026.
  • Seneschal Advisors sold 1 Summit Therapeutics share in Q1 2026, an estimated $16.
  • Summit Therapeutics made up ﹤0.01% of Seneschal Advisors's portfolio in Q1 2026, its #593 holding.
  • Seneschal Advisors first reported a position in Summit Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Seneschal Advisors's Summit Therapeutics position peaked at $42 in Q3 2025.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Seneschal Advisors's 13F filing for Q1 2026, filed 8 May 2026.